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In genetic diseases, where the cells are already damaged, the damaged cells can be replaced by new normal cells, which can be
diﬀerentiated from iPSC. To avoid immune rejection, iPSC from the patient’s own cell can be developed. However, iPSC from the
patients’s cell harbors the same genetic aberration. Therefore, before diﬀerentiating the iPSCs into required cells, genetic repair
should be done. This review discusses the various technologies to repair the genetic aberration in patient-derived iPSC, or to
prevent the genetic aberration to cause further damage in the iPSC-derived cells, such as Zn ﬁnger and TALE nuclease genetic
editing, RNA interference technology, exon skipping, and gene transfer method. In addition, the challenges in using the iPSC and
the strategies to manage the hurdles are addressed.
1.Introduction
Since the ﬁrst generation of induced pluripotent stem cell
(iPSC) from mouse adult ﬁbroblast using four inducing
factors by Takahashi and Yamanaka in 2006 [1], followed
by the generation of human iPSC [2], various vectors to
introduce various inducing factors have been published, and
various combinations of the inducing factors, in the form of
transcription factors or microRNA, were used. Further, there
are chemical compounds, for example, butyrate that may
enhance the inducing capacity of the transcription factors
[3], so that Oct 4 alone is enough to induce somatic cells into
iPSC [4].
Further, various patient-derived iPSCs were developed
that may be used to reveal the pathogenesis of various
genetic diseases. These genetic abnormality-harboring iPSCs
may be repaired, and the genetically repaired iPSC may be
diﬀerentiated into normal required cells [5]. In the future,
these patient-derived normal cells may be used to a patient-
tailored therapy to replace the damaged cells due to the
disease.
To date, iPSCs for various genetic diseases have been
developed, such as for certain type of Parkinson’s disease [5],
spinal muscular atrophy [6], lentigines, electrocardiographic
abnormalities,ocularhypertelorism,pulmonaryvalvesteno-
sis, abnormal genitalia, retardation of growth, and deafness
(LEOPARD)syndrome[7],longQ-Tsyndrome[8],Timothy
syndrome [9], Hurler syndrome [10], epidermolysis bullosa
[11], and thalassemia [12].
TheiPSCresemblesembryonicstemcellinthediﬀerenti-
ation capacity into various kinds of cells and in inducing ter-
atoma in laboratory animal [1]. However, various researches
have shown that iPSC is not identical to embryonic stem
cell. Moreover, various aberrations, which may arise during
induction or subsequent propagation, pose challenges in the
use of iPSC for the cure of genetic diseases.
Therefore, this review discusses the prospect of iPSCs
to cure genetic disease, in term of the eﬃcient methods for
genetic repair that may be used to repair genetic disease-
harboring iPSCs, and the challenges that should be resolved
when iPSCs are to be used to cure genetic diseases.
2. Methods for GeneticRepair
To date, there are several eﬃcient methods for genetic repair
of genetic diseases, that is, zinc ﬁnger and transcription
activator-like eﬀector (TALE) nuclease method, RNA2 Stem Cells International
interference (RNAi), exon skipping technology, and gene
transfer. However, when the cells are already damaged,
they should be replaced by new normal cells, which can be
diﬀerentiated from iPSC. Those methods may be used to
repair the genetic disease-harboring cells that may be done
either in the somatic cells before induction to pluripotency
[13], or somatic cell derived iPSC [5].
2.1. Zinc Finger Nuclease Method. The zinc ﬁnger nuclease
method is one of the eﬃcient genetic editing methods.
A Zn ﬁnger nuclease consists of a Zn ﬁnger domain and
FokI endonuclease. The Zn ﬁnger domain contains Zn
ﬁnger motifs that recognize and bind to a speciﬁc DNA
sequence. The FokI endonuclease works as a dimer to cause a
double-strand break (DSB) in the DNA. Therefore, Zn ﬁnger
nucleases should work in pairs. One of the Zn ﬁnger motifs
recognizesandbindstothesequenceupstreamandtheother
to the sequence down stream to the site to be cleaved by
the endonuclease (Figure 1). Principally, a certain Zn ﬁnger
nucleasecanbeengineeredtorecognizeanyspeciﬁcsequence
and to cause a DSB at any speciﬁc site. The DSB is then
repaired by homologous recombination, which is facilitated
bythe presence ofexogenous donor DNA homologous tothe
sequence to be repaired, or by error-prone nonhomologous
end joining [14, 15]. To deliver the Zn ﬁnger nucleases into a
cell, an expression vector containing the Zn ﬁnger nucleases
can be engineered. The results of this genetic editing may
be either mutation repair or insertion of a certain DNA
sequence, when a certain exogenous donor DNA is used, or
error prone repair when no donor DNA is used, or deletion
when two pairs of Zn ﬁnger nucleases are used and causing
2D S B[ 15]. Therefore, this method may be used to correct
a mutation, or to insert or delete a certain DNA sequence
(Figure 2).
As t u d yu s e de x o g e n o u sd o n o rD N At h a tw a sp a c k e di n
a double-stranded plasmid, or in the form of a single-strand
oligodeoxynucleotide. This method was successfully used to
repair a point mutation A53T (G209) in α-synuclein gene
in a Parkinson’s disease patient-derived iPSC. Further, the
repaired iPSC was successfully diﬀerentiated into functional
dopaminergic neurons [5].
A drawback of this method is oﬀ target DSB due to
homodimerization, which may cause undesired mutation
or cytotoxicity. Therefore, genome-wide putative-oﬀ target
mutation assay should be performed, to ascertain that there
is no oﬀ-target mutation in the genetically repaired iPSC [5].
Recently, to reduce oﬀ-target DSB, engineered FokI nuclease
that cannot form a homodimer was developed. This method
showed that the obligate FokI heterodimer greatly reduces
the oﬀ target DSB [16, 17].
2.2. TALE Nuclease Method. Transcription activator-like
eﬀectors from a plant pathogen, the Xanthomonas sp.,a r e
sequence-speciﬁc DNA-binding proteins. As Zn ﬁngers,
TALEs can be engineered to bind to any speciﬁc sequence,
and linked to a FokI nuclease to work in pair and cleave
the sequence [18, 19]. This method was tested in iPS and
showed that TALE nuclease mediated site-speciﬁc genetic
ds DNA
ds DNA with DSB
FokI endonuclease
Zn ﬁnger 1
Zn ﬁnger 2 
Figure 1: Generation of a double strand break by zinc ﬁnger
nucleases, ds: double strand, DSB: double strand break, Zn: zinc.
modiﬁcation with similar precision and eﬃciency as Zn
ﬁnger nuclease [20], but with lower degree of oﬀ target
activity and cytotoxicity [21].
2.3. RNA Interference (RNAi) Technology. RNA interference
involves micro- (mi-)RNA and small interfering (si)RNA,
which,uponbase-pairingtotheirtargetsequenceinacertain
mRNA, cause degradation or prevent translation of the
mRNA [22]. This method may be useful to suppress the
expression of a toxic mutant allele that causes the symptoms
of a certain genetic disease. However, this method does
not repair the underlying genetic aberration. Therefore, to
suppress the expression of the mutant allele in a genetically
abnormal iPSC, a method to continuously deliver the
interfering RNA is needed.
Various expression systems for either miRNA or siRNA
have been developed using various vectors and promoters
[23–27]. The expression system for siRNA involves the
formation of short hairpin (sh)RNA before the formation
of a double-strand functional siRNA, while that for miRNA
involves the formation of primary miRNA transcripts,
followed by the formation of pre-miRNA, and ﬁnally a
functional mature miRNA [23, 24].
However, the use of strong promoter results in high level
expression of miRNA or shRNA that may lead to cytotoxicity
[28–30]. Cytotoxicity of siRNA expression system may be
due to competition of the artiﬁcial with the natural RNA
interference system and lead to disruption of the natural
system [31], or oﬀ-target silencing [32], possibly due to
miRNA-like binding of siRNA at the 3 UTR region [33].
In addition, shRNA or the viral vector may induce cellular
interferon response that leads to universal silencing [34, 35].
Comparison between miRNA and siRNA expression
systemshowedthatsiRNAwasmorepotent[36],butmiRNA
expression system was safer [31, 37, 38]. Cytotoxicity and oﬀ
target eﬀect of siRNA can be reduced by reducing the siRNA
concentration [33]. Therefore, using less potent promoterStem Cells International 3
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Figure 2: Possibilities of genetic repair using zinc ﬁnger nucleases, ds: double-strand, DSB: double-strand break, NHEJ: non-homologous
end joining.
in siRNA expression system may resolve the problem.
Alternatively, engineering a single nucleotide bulge in the
siRNA expression system may overcome the problem [39].
This RNA interference technology was proven useful to
suppress the expression of a mutant allele in Alzheimer’s
disease in cell culture [40], spinocerebellar ataxia [23],
Huntington’s disease [41], and amyotrophic lateral sclerosis,
in animal models [42, 43].
2.4. Exon Skipping Technology. Exon skipping technology
causes deletion of selected exon(s) by targeting a sequence in
the adjacent intron using an antisense oligonucleotide. This
method can be used in genetic aberration where there is a
mutation that causes a frameshift or a stop in the mRNA,
and deletion of one/several frame-shifted exon(s) leads to a
shorter, but still functional protein, for example, dystrophin
in Duchene muscular dystrophy (DMD) [44].
However, the use of exogenous antisense oligonucleotide
to cause exon skipping in iPSC needs continuous supply
of the antisense oligonucleotide. Therefore, to repair a
genetic aberration in iPSC, an expression vector needs to be
engineered.
A study on DMD mouse model used an expression
vector to deliver the antisense oligonucleotide by a single-
dose injection into skeletal muscle. The expression vector
was engineered using AAV-2-based vector combined to a
modiﬁed U7 small nuclear (sn)RNA, which was linked to
the antisense sequence to both ﬂanking intron of the exon(s)
to be deleted. The U7 snRNA guides the antisense sequence
to the proper subcellular site and facilitates splicing and
exon skipping. The study showed a sustained production
of functional dystrophin and correction of the muscular
dystrophy [44]. Another study used the same method but
administered the expression vector into the hippocampus
and showed normalized synaptic plasticity [45].
2.5. Gene Transfer Method. Gene transfer method may be
useful in genetic diseases where there is genetic aberration
that causes the absence of expression of a certain gene,
such as in tyrosinemia type 1 due to fumarylacetoacetate
hydrolase (FAH) deﬁciency [46], β thalassemia [12], and
Fanconi anemia [13] .As t u d yh a sd e v e l o p e da ni P S Cf r o m
an FAH deﬁcient mouse, corrected the genetic aberration
by transduction of FAH cDNA using lentiviral vector, and
successfully generated healthy mice from the corrected iPSC
[46].
3. Challenges inUsing iPSCs
AsiPSCresemblesembryonicstemcellinteratoma-inducing
capacity, and the detection of various genetic and epigenetic
aberrations, caution should be paid to solve these problems.
Moreover, delivery route and the high cost in this patient-
tailored therapy may pose other problems. Further, there is
stillaquestionofwhichcelltypeshouldbediﬀerentiatedand
transplanted, whether the diﬀerentiated iPSCs can integrate
and cooperate with other cells in the target site, and whether
the diﬀerentiated iPSC is not rejected by the immune
system. Finally, safety issues concerning the use of genetically
repaired iPSC need to be considered.
3.1. Teratoma-Inducing Capacity. Theoretically, iPSC can
be diﬀerentiated into any required cells. A study on
human embryonic stem cells used multiple passages under
diﬀerentiation-inducing condition to eliminate residual
tumor-forming cells and proved the absence of pluripotent
cells using Oct3/4 marker, and by grafting the diﬀerenti-
ated cells in rats [47]. However, human iPSC line-derived
dopaminergic neuron progenitor transplantation in a rat
model showed the presence of Nestin-positive tumor-like
cells at the site of transplantation [48].
Therefore, to prevent tumor formation in patients
receiving transplantation of diﬀerentiated iPSC, it should
be ascertained that the diﬀerentiated cells are free from
residual pluripotent iPSC, and methods should be developed
to purify the diﬀerentiated iPSC and to check the absence of
tumorigenic potential in the desired cells.
3.2. Genetic and Epigenetic Aberrations. Ar e c e n ts t u d y
showed that there were variations in the copy number of
certain genes in the form of duplications and deletions, in
human iPSC [5, 49–51]. Another study showed that there
were point mutations in certain somatic protein-coding
genes [52].4 Stem Cells International
Apart from teratoma-inducing capacity of iPSC, copy
number variation may be present in the form of ampliﬁca-
tion of oncogenes or deletion of tumor suppressor genes that
mayleadtotumorformation.Moreover,pointmutationmay
lead to either up regulation or down-regulation of certain
important genes other than tumor-related genes. Therefore,
caution is warranted before iPSC-derived cells are used in
therapy. Substantial genetic abnormalities may be observed
by chromosomal analysis, but subtle changes need more
careful examination.
An epigenetic study showed aberrant DNA methylation
of certain single bases in human iPSC [53]. Moreover,
comparison of human iPSC developed from various types of
cells representative of ectoderm, mesoderm, and endoderm
revealed retention of transcription memory of the original
cells due to incomplete promoter DNA methylation [54].
A study on DNA methylation and transcription proﬁles of
20 diﬀerent human embryonic stem cell and 12 iPSC lines
showed large variations [55]. Analysis of methylation and
transcription proﬁles [54], and transcription and expression
proﬁles enable the prediction of a cell line eﬃciency to be
diﬀerentiated into a certain required cell type [56].
Therefore,beforeattemptstoinduceiPSCfromapatient,
determination of the iPSC-derived cells that are required to
replace damaged cells may be useful in choosing the cell
source for iPSC induction. Using a cell from the same germ
layer as the desired diﬀerentiated cell is an advantage.
3.3. Delivery Route. Delivery route depends on the cells,
tissue, or organ to be repaired, which may not be the same
for all diseases. For some diseases, the target site may be
diﬃcult to reach, for example, Alzheimer, Parkinson’s, and
other neurological disease, where the target site is inside the
brain. Attempts to deliver cells into the brain have been done
and showed variable results [57, 58]. Therefore, the simplest
way is intravenous delivery. However, it is still a question
whether the cells home to the intended target site.
A study on intravenous injection of either bone marrow
mesenchymal stem cells or epidermal neural crest stem cells
in an animal model showed that both types of cells homed
into inﬂamed corpus callosum. The result of the study
suggests that intravenous delivery may work on neurodegen-
erative diseases where inﬂammation is present on the target
site [59].
Therefore, for each genetic disease, studies are highly
needed to identify the most eﬀective, eﬃcient, and safe route
of delivery.
3.4. High Cost in Developing a Patient-Tailored Therapy.
The possibility to repair genetic defect in patient-derived
iPSC may lead to individual patient-tailored therapy for
genetic diseases. This approach has an advantage compared
to allogenic cell therapy, as no immunosuppressive regiment
is required, though a study showed that autologous iPSC
may elicit immune response [60]. However, the presence
of genetic abnormality in various iPSCs necessitates careful
screening to ensure the safety of iPSC-derived diﬀerentiated
cells. To date, technologies to check subtle abnormalities,
such as copy number variation and genome wide mutation
analysis, are available, though they need a high cost.
Therefore, for each genetic disease, development of eﬃcient,
eﬀective, and economical method to screen and check the
safety of the desired cells is highly needed.
3.5. Type of Cell to Be Transplanted and Integration into
the Target Site. Requirement of cell type depends on the
damaged cells due to the genetic disease. The option is
whether to use fully or partly diﬀerentiated iPSC. Transplan-
tation of partly diﬀerentiated iPSC is intended to resume the
diﬀerentiation in vivo into the mature desired cells.
A study showed that in vitro diﬀerentiated murine iPSC-
derived neurons functionally integrated into the brain and
alleviated the symptoms in Parkinson’s rat model [61].
Another study on embryonic stem-cell-derived neural stem
cells that were transplanted in the putamen of a Parkinson’s
disease animal model showed that the transplanted cells
diﬀerentiated in vivo into functional dopaminergic neurons
[62].
Therefore, studies are required for each genetic disease
to determine which cell type and degree of diﬀerentiation
give the best result in term of cell function, integration, and
cooperation with surrounding cells, which ﬁnally alleviate
the symptoms.
3.6. Immune Rejection Problem. Using patient’s own cells to
provide iPSC-derived cells is believed to handle immune
rejection problems. However, a recent study showed that
even the patient’s own iPSC may induce immune rejection
[60]. Moreover, when viral vectors are used to engineer
the expression vector for the various methods for genetic
repairs or to repress the symptoms, immune rejection may
be developed towards the viral vectors. A study showed that
viral vectors induced adaptive immune response in vivo [63],
which leads to inﬂammatory responses [64]. In addition,
innateimmunerejectionmaybedevelopedtowardstheRNA
in case exon skipping or RNA interference method is used.
Several studies showed interferon production due to RNA-
expressing vectors in vitro [34, 35], which can be overcome
by reducing the length of RNA to below 21-mers [35].
Although in iPSC genetic repair, the expression vector
is transduced into the iPSC, and the presence in blood
or tissue may be minimal to be able to induce immune
response, studies are highly needed to ﬁnd a method to cope
with immune rejection problems and to ascertain that the
corrected iPSC is really safe and will not be rejected.
3.7. Safety Issues in Using Genetically Repaired iPSC. Most of
the methods of genetic repair, which may be used to repair
patient-derived iPSC, use viral vectors as expression vectors,
such as lentiviral-based vector in gene transfer technology
[13], TALE nuclease genetic editing [18], RNAi technology
[24, 25], or AAV-based vector in RNAi technology [29]a n d
exon skipping technology [44, 45].
Viral vectors especially lentiviral-based vectors are
known to cause side eﬀects that range from immortalization
to clonal dominance in vitro, and oncogenesis in vivo,d u et oStem Cells International 5
integration of the vector into host genome. The integration
or insertional mutagenesis activates the expression of a pro-
tooncogene or cancer promoting genes near the integration
site [65].
Therefore, it is very important to address the clinical
safety of the vectors. This purpose can be achieved by
deletion of promoter element in the viral long terminal
repeat (LTR), which is termed self-inactivating (SIN) LTR,
which may signiﬁcantly decrease cellular transformation in
vitro.Anotherapproachtoreduceoncogenesisisbyinsertion
ofaninsulatorelementintotheLTR[65].Thus,vectordesign
and safety assessment of the vector before constructing an
expression vector for the purpose of genetically repairing
iPSC is of high importance.
4. Conclusion
Induced pluripotent stem cells are very promising as the
source of the required cells to replace the damaged cells in
various genetic diseases. However, further studies are needed
to resolve the various challenges.
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